BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27146742)

  • 1. Occurrence of myelodysplasia/acute myeloid leukemia 'on therapy' in two patients with acute promyelocytic leukemia.
    Chelghoum Y; Plesa A; Ducastelle S; Elhamri M; Thomas X
    Indian J Cancer; 2016; 53(1):59-60. PubMed ID: 27146742
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy-related MDS and AML in acute promyelocytic leukemia.
    Andersen MK; Pedersen-Bjergaard J
    Blood; 2002 Sep; 100(5):1928-9; author reply 1929. PubMed ID: 12211197
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL).
    Garcia-Manero G; Kantarjian HM; Kornblau S; Estey E
    Leukemia; 2002 Sep; 16(9):1888. PubMed ID: 12200720
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T; Yasuyama M; Kawauchi K
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
    Miyawaki S
    Rinsho Ketsueki; 2014 Jan; 55(1):31-41. PubMed ID: 24492035
    [No Abstract]   [Full Text] [Related]  

  • 6. Updates on the treatment of acute promyelocytic leukemia.
    Tallman MS
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):89-90. PubMed ID: 20386527
    [No Abstract]   [Full Text] [Related]  

  • 7. Central nervous system relapse in acute promyelocytic leukemia.
    Colovic N; Bogdanovic A; Miljic P; Jankovic G; Colovic M
    Am J Hematol; 2002 Sep; 71(1):60-1. PubMed ID: 12221680
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Zhang X; Guo X
    Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
    Egyed M; Rumi G; Boros B; Páldi-Haris P; Földi J
    Leukemia; 2000 Jun; 14(6):1153. PubMed ID: 10865982
    [No Abstract]   [Full Text] [Related]  

  • 10. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of high-risk acute promyelocytic leukemia in very elderly patients using all-trans retinoic acid plus reduced-dose idarubicin.
    Fujisawa T; Takeda J; Aoki K; Ishikawa T
    Ann Hematol; 2014 Sep; 93(9):1621-3. PubMed ID: 24399307
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia.
    Teng HW; Bai LY; Chao TC; Wang WS; Chen PM
    Jpn J Clin Oncol; 2005 Feb; 35(2):94-6. PubMed ID: 15709095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation.
    Breccia M; Cimino G; Alimena G; De Carolis S; Lo Coco F; Mandelli F
    Haematologica; 2002 Feb; 87(2):ELT12. PubMed ID: 11836189
    [No Abstract]   [Full Text] [Related]  

  • 15. Automated differential counts in acute promyelocytic leukemia patients may be misleading.
    Kapelushnik J; Kafka M; Moser A; Yermiahu T
    Med Pediatr Oncol; 2002 Apr; 38(4):269-70. PubMed ID: 11920794
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
    Schlenk RF; Germing U; Hartmann F; Glasmacher A; Fischer JT; del Valle y Fuentes F; Götze K; Pralle H; Nerl C; Salwender H; Grimminger W; Petzer A; Hensel M; Benner A; Zick L; Döhner K; Fröhling S; Döhner H;
    Leukemia; 2005 Jun; 19(6):978-83. PubMed ID: 15843821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
    Mallo M; Salido M; Espinet B; Cervera J; Canellas A; Pajuelo JC; Pedro C; Florensa L; Sanz MA; Solé F
    Leuk Res; 2007 Sep; 31(9):1315-7. PubMed ID: 17092559
    [No Abstract]   [Full Text] [Related]  

  • 18. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
    Parajuli R; Altman J; Kuzel T; Perdekamp M; Tallman M
    Am J Hematol; 2010 Oct; 85(10):829. PubMed ID: 20721888
    [No Abstract]   [Full Text] [Related]  

  • 20. Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip.
    Agarwal N; Tepe EM; Mishra A; Ward JH
    Ann Hematol; 2006 Oct; 85(10):741-2. PubMed ID: 16718497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.